Michael Schmitz
Stock Analyst at Guggenheim
(2.03)
# 3,014
Out of 4,959 analysts
7
Total ratings
66.67%
Success rate
0.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Buy | $45 | $38.63 | +16.49% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $37.01 | +121.56% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $67.45 | +64.57% | 2 | Oct 1, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $7.32 | +446.45% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.15 | - | 1 | Jan 3, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $38.63
Upside: +16.49%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $37.01
Upside: +121.56%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $67.45
Upside: +64.57%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $7.32
Upside: +446.45%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -